Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly raised “tens of millions” of renminbi in a Series C1 financing round led by Qiaodao Investment Fund. The proceeds will be used to further develop and commercialize the company’s innovative molecular diagnostics products.
Company Profile
Founded in 2017, Rainsure Scientific has established a strong presence in the global life sciences market. The company’s wholly owned subsidiary, PreciGenome LLC, is based in the United States, where its life science products have been adopted by leading institutions such as Yale and Harvard Medical School. Rainsure Scientific’s molecular diagnostics product is recognized as the only PCR system in China with market approvals in China, the United States, and Europe. Additionally, its products are widely used in top-tier hospitals in China, including Ruijin Hospital and Huashan Hospital.
Future Implications
The Series C1 financing round marks a significant milestone for Rainsure Scientific, positioning the company to accelerate its R&D efforts and expand its market reach. This investment will support the development of next-generation PCR systems and enhance the company’s ability to meet growing global demand for advanced molecular diagnostics solutions.-Fineline Info & Tech
